Quantitative and noninvasive assessment of chronic liver diseases using two-dimensional shear wave elastography

Li-Ting Xie, Chun-Hong Yan, Qi-Yu Zhao, Meng-Na He, Tian-An Jiang

Two-dimensional shear wave elastography (2D-SWE) is a rapid, simple and novel noninvasive method that has been proposed for assessing hepatic fibrosis in patients with chronic liver diseases (CLDs) based on measurements of liver stiffness. 2D-SWE can be performed easily at the bedside or in an outpatient clinic and yields immediate results with good reproducibility. Furthermore, 2D-SWE was an efficient method for evaluating liver fibrosis in small to moderately sized clinical trials. However, the quality criteria for the staging of liver fibrosis are not yet well defined. Liver fibrosis is the main pathological basis of liver stiffness and a key step in the progression from CLD to cirrhosis; thus, the management of CLD largely depends on the extent and progression of liver fibrosis. 2D-SWE appears to be an excellent tool for the early detection of cirrhosis and may have prognostic value in this context. Because 2D-SWE has high patient acceptance, it could be useful for monitoring fibrosis progression and regression in individual cases. However, multicenter data are needed to support its use. This study reviews the current status and future perspectives of 2D-SWE for assessments of liver fibrosis and discusses the technical advantages and limitations that impact its effective and rational clinical use.

Key words: Elastography; Shear wave; Chronic liver disease; Liver fibrosis

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: There has been considerable research in recent years dedicated to the development of noninvasive methods of chronic liver diseases (CLDs). These include novel elastography methods. In this review, we outline the current state and future perspectives of the commonly used two-dimensional
shear wave elastography (2D-SWE) in CLDs. In particular, we discuss the applications and problems in chronic viral hepatitis, nonalcoholic fatty liver disease, alcoholic liver disease, liver transplantation, focal liver lesions, and autoimmune liver disease to synthesize existing evidence for the reader. This is the first full and complete review to assess various CLDs using 2D-SWE.

Xie LT, Yan CH, Zhao QY, He MN, Jiang TA. Quantitative and noninvasive assessment of chronic liver diseases using two-dimensional shear wave elastography. World J Gastroenterol 2018; 24(9): 957-970 Available from: URL: http://www.wjgnet.com/1007-9327/full/v24/i9/957.htm DOI: http://dx.doi.org/10.3748/wjg.v24.i9.957

INTRODUCTION
Liver fibrosis results from repetitive or sustained liver inflammation caused by chronic liver diseases (CLDs) and has serious long-term consequences in terms of patient morbidity and mortality due to the progression to cirrhosis. Patients with cirrhosis are at a higher risk of developing complications, including esophageal varices, ascites, liver failure and hepatocellular carcinoma (HCC), than healthy individuals. Liver fibrosis is an important factor in the development of various CLDs and is mainly mediated by chronic liver injury, which leads to liver fibrosis characterized by increased extracellular matrix production by fibroblast-like cells and increased liver stiffness (LS). The precise assessment of the severity of liver fibrosis and reliable diagnosis of cirrhosis are vital steps in the management of CLDs, as they provide information that impacts therapeutic decisions.

Liver biopsy remains the reference standard for the staging of liver fibrosis, despite its limitations, including its invasivity and the pain experienced by patients, high cost, risk of bleeding and poor reproducibility, and contraindications, such as cases of massive ascites. Liver fibrosis is influenced by several factors, including intra- and interobserver variability and sampling error. Given these limitations, liver biopsy is not an ideal method for repeated assessments of disease progression as well.

The noninvasive assessment of liver fibrosis has recently become a research focus, leading to the introduction of new technologies. In particular, shear wave elastography (SWE), which is based on ultrasound (US) technology, has been widely applied and has gained acceptance. The latest guidelines on the clinical use of liver US elastography of the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) and the guidelines on the evaluation of liver disease severity and prognosis of the European Association for the Study of the Liver - Asociación Latinoamericana para el Estudio del Hígado state that two-dimension (2D)-SWE is a valid and promising technique for noninvasive staging of liver fibrosis in viral hepatitis and seems to be at least equivalent to transient elastography (TE) and point SWE (pSWE)/acoustic radiation force impulse (ARFI).

BASICS OF 2D-SWE

Comparison of elastography methods
Several elasticity imaging techniques have recently been developed for assessing the mechanical properties of liver tissues and staging the fibrosis level using different imaging modalities. In accordance with the Guidelines for the Basic Principles and Technology of EFSUMB, the available US-based elastography techniques include strain elastography (SE) and SWE; SWE can be further subdivided into three techniques - TE, pSWE and 2D-SWE - in addition to radiology-based magnetic resonance elastography (MRE).

Among these, TE is the most widely used elastography method. However, in a study of 13369 CLD patients over a 5-year period of using TE, unreliable results were obtained in 15.8% of cases. The limitations of TE, such as the difficulty in measuring obese patients and patients with narrow intercostal spaces, the variations in operator experience, and the fact that it is not applicable in patients with ascites, were the primary factors contributing to these unreliable results. Importantly, the issue of obesity has been partially addressed by the introduction of specially designed XL probes that measure LS deeper than the standard M probes. It has also been reported that TE and ARFI elastography are inaccurate in the detection of early and intermediate fibrosis.

MRE can be used to quantitatively diagnose liver fibrosis with high accuracy and is mainly used for the diagnosis of advanced liver fibrosis and cirrhosis. The diagnostic accuracy of MRE increased when the liver fibrosis was getting serious, whereas the level of early fibrosis detected by MRE is inaccurate. 2D-SWE is the latest elastography technology and can assess the elasticity of liver tissue easily and quickly, thus reflecting the degree of liver fibrosis. Table 1 demonstrates the comparison of currently available noninvasive methods in patients with CLD.

Principles of 2D-SWE

2D-SWE is a novel noninvasive method that has been proposed for assessing LS by measuring the velocity of elastic shear waves in the liver parenchyma. In SWE, shear waves are created by US-generated pulses of an acoustic radiation force (Figure 1). The velocity of the shear wave is then estimated by a Doppler-like effect over a region of interest (ROI) and is related to the stiffness or elasticity of the medium. This shear wave velocity can be used to calculate the tissue stiffness by the formula $E = \rho c^2$, where $E$ is tissue elasticity (Young’s modulus, kPa), $\rho$ is tissue density (kg/m$^3$), and $c$ is shear wave velocity (m/s).

WJG | www.wjgnet.com
Elastography is shown on a color-coded image displayed on a B-mode image. Then, with the ROI on the elasticity image, the mean, maximal and minimal LS values within the ROI can be visualized on a screen, along with the standard deviation (SD) of the measured elasticity. The size and position of the ROI can be modified by the operator based on the specific goals of each liver assessment (Figure 2). In general, red areas indicate larger Young’s modulus of stiffer tissues, while blue areas indicate smaller Young’s modulus of softer tissues.

### Examination technique

2D-SWE examination of the liver is performed by using convex US probes with integrated technological solutions allowing elasticity imaging and measurements, according to the World Federation for Ultrasound in Medicine and Biology and the EFSUMB Guidelines for the Clinical Use of US Elastography, as well as the Society of Radiologists in Ultrasound Consensus Conference Statement regarding the assessment of liver fibrosis by elastography. The proper examination procedure is described in Table 2, and the precautions

---

**Table 1 Comparison of currently available noninvasive methods in patients with chronic liver disease**

| Content | TE | pSWE | 2D-SWE | MRE |
|---------|----|------|--------|-----|
| Technical principle | TE was the first commercially available elastography method developed for measuring liver stiffness using a dedicated device that includes an amplitude modulation (A) mode image for organ localization | pSWE can be implemented on a common ultrasound diagnostic system. It uses a regular ultrasonic probe to emit a single impulse of acoustic radiation force and generates a shear wave to detect the shear wave propagation velocity | 2D-SWE is the combination of a radiation force applied to the tissues by focused ultrasonic beams and a very high frame rate US imaging sequence, which is able to capture the propagation of resulting the shear waves in real time | MRE enables the measurement of liver stiffness with an MRI-compatible generator; mechanical shear waves are delivered to the tissue and displayed as elastograms using phase-contrast image sequences |
| Reference point | Young’s modulus (kPa) | Shear wave speed (m/s) | Shear wave speed (m/s) | Shear wave speed (m/s) |
| Selected example | FibroScan (Echosens, France) | VTQ using ARFI imaging (Siemens Healthcare, Germany) | ElastPQ (Philips Healthcare, Netherlands) | Shear Wave Measurement (Hitachi Aloka Medical, Japan) |
| Advantages | Most widely used and validated technique | Can be performed using a regular US machine | Can be performed using a regular US machine | Can be performed using a regular MRI machine |
| | Quality criteria well defined | The ROI can be positioned under B-mode visualization | Simple and fast to use | Good stability and reproducibility |
| | User friendly, rapid, easy to measure at the bedside | Higher applicability than TE (not limited by ascites or obesity) | The ROI can be positioned under B-mode visualization | Scans the whole liver |
| | Good reproducibility | pSWE is equal to the performance of TE for significant fibrosis and cirrhosis | A larger ROI than that of TE and pSWE | Higher applicability than TE (not limited by ascites or obesity) |
| | Good performance for noninvasive assessments of liver fibrosis staging | Excellent diagnostic accuracy for excluding liver cirrhosis | Good applicability (not limited by ascites or obesity) | Excellent diagnostic accuracy for noninvasive staging of liver fibrosis and cirrhosis |
| | Prognostic value in cirrhosis | | Good stability and reproducibility | |
| Disadvantages | Requires a special device and probe | ROI size is smaller than that of TE and cannot be modified | Time-consuming | |
| | ROI size is rather small and cannot be chosen | Quality criteria not yet well defined | Even more costly than SWE and TE | |
| | Lack of applicability (limited by ascites, severe obesity) | Narrow range of values | Failure can occur due to claustrophobia and iron overload | |
| | No B-mode orientation | Unable to distinguish between intermediate stages of liver fibrosis | Affected by respiratory movement | |
| | Cannot avoid large vessels or the gallbladder | | Hepatic MRE signal may be so low that waves cannot be adequately visualized with a gradient-echo based MRE sequence | |

2D-SWE: Two-dimensional shear wave elastography; MRE: Magnetic resonance elastography; MRI: Magnetic resonance imaging; pSWE: Point shear wave elastography; ROI: Region of interest; TE: Transient elastography; US: Ultrasound; VTQ: Virtual touch tissue quantification.
The primary aim of treatment is controlling the progression of liver failure. In these cases, prognosis and treatment are closely linked to complications such as portal hypertension (PH), advanced liver fibrosis from chronic viral hepatitis B (CHB), and hepatitis C (CHC), respectively. Worldwide, approximately 248 million people suffer from chronic hepatitis B (CHB) and 185 million from CHC. Viral hepatitis is a global public health issue, with various results for check-up and who have no overt causes of liver disease, normal liver enzymes. Various results for healthy subjects who have undergone a professional check-up and who have no overt causes of liver disease, with normal liver enzymes. Various results for normal LS values are shown in Table 4.

Normal value

"Normal” LS values have recently been studied in healthy subjects who have undergone a professional check-up and who have no overt causes of liver disease, with normal liver enzymes. Various results for normal LS values are shown in Table 4.

**Table 2** Procedures of two-dimensional shear wave elastography

| Key points               | Procedures                                                                 |
|--------------------------|-----------------------------------------------------------------------------|
| Adequate preparation     | • Fast and rest before the exam                                            |
|                          | • Perform in a supine position                                             |
|                          | • Train the patients on breathing                                          |
| Accurate positioning     | • Scan the 6/7/8 intercostal spaces of the right liver                     |
|                          | • Acquire stable and high-quality images                                   |
|                          | • Instruct the patient to hold the breath for 3-5 s                       |
| Stable measurement       | • Switch to SWE mode                                                       |
|                          | • Freeze the image and adjust the position of the ROI                     |
|                          | • Calculate the LS automatically                                         |
|                          | • Average the repeated measurement values                                 |

LS: Liver stiffness; ROI: Region of interest; SWE: Shear wave elastography.

**Figure 1** The principle of two-dimensional shear wave elastography. 2D-SWE is created by ultrasound-generated pulses from an acoustic radiation force that produce plane shear waves, and the propagation of the resulting shear waves can be captured in real time. 2D-SWE: Two-dimensional shear wave elastography.

and techniques of 2D-SWE in Table 3.

**Normal value**

"Normal” LS values have recently been studied in healthy subjects who have undergone a professional check-up and who have no overt causes of liver disease, with normal liver enzymes. Various results for normal LS values are shown in Table 4.

**CLINICAL APPLICATIONS OF 2D-SWE**

**Diagnosis of chronic viral hepatitis**

Viral hepatitis is a global public health issue, with approximately 248 million and 185 million people worldwide suffering from chronic hepatitis B (CHB) and hepatitis C (CHC), respectively. Patients with advanced liver fibrosis from chronic viral hepatitis have a high risk of developing liver cancer and related complications, including portal hypertension (PH), esophageal and gastric variceal bleeding (EGVB), and liver failure. In these cases, prognosis and treatment are mainly affected by the degree of fibrosis, and the primary aim of treatment is controlling the progression of liver fibrosis. The clinical practice guidelines for the management of CHB and CHC of the European Association for the Study of the Liver (EASL) as well as the World Health Organization Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection, recommend elastography as a routine method for clinically evaluating liver fibrosis to avoid the need for liver biopsy in some patients.

Recent studies performed worldwide have focused on 2D-SWE for determining the role of viral hepatitis in liver fibrosis. In one study, 45 n CHB patients were examined by 2D-SWE and TE. The results showed that 2D-SWE provided a more accurate correlation of liver elasticity with liver fibrosis stage than TE, especially for the identification of significant fibrosis (≥F2). Bavu et al examined 113 CHC patients and found that SWE performed better diagnostically for early, intermediate and advanced predicted levels of fibrosis than TE. Ferraioli et al. used biopsy as a reference to assess the accuracy of SWE and TE in 121 CHC patients; they found that real-time SWE was more accurate than TE for assessing significant fibrosis (≥F2). These results were strongly supported by three meta-analyses published by other authors. In addition, a recent large-sample meta-analysis concluded that SWE was more accurate for advanced fibrosis (≥F3) and cirrhosis (F4). What’s more, Grgurevic et al. evaluated the performance of real-time 2D-SWE for quantitatively assessing liver and spleen stiffness in patients with chronic viral hepatitis. They showed that real-time 2D-SWE can accurately identify various degrees of liver fibrosis and cirrhosis and demonstrated that liver and spleen stiffness continue to increase even after cirrhosis has developed. In fact, they noticed that spleen and liver stiffness tended to converge in more advanced stages of liver cirrhosis. This is an important study showing that 2D-SWE can be used to study the evolution of liver disease beyond cirrhosis.

As described above, SWE has high accuracy and specificity for assessing liver fibrosis due to chronic viral hepatitis, which makes it convenient for the real-time clinical monitoring of liver fibrosis. SWE technology is expected to replace biopsy, thereby eliminating the invasiveness and poor reproducibility of the latter technique. However, the quality criteria for the staging of liver fibrosis are not yet well defined. In addition, 2D-SWE has shown different diagnostic accuracies for liver fibrosis in patients with CHB and CHC. We suppose that this is probably due to the different etiologies of hepatitis B virus (HBV) and hepatitis C virus that lead to different tissue patterns and distributions of fibrosis development. Specifically, cirrhosis patients tend to produce larger regenerative nodules, which may result in different LS measurements if the ROI is placed in such an area. These findings suggest that assessments of the degree of liver fibrosis in different liver diseases cannot be based on the same diagnostic criteria, leading to distinct treatment strategies.

**Figure 1** The principle of two-dimensional shear wave elastography. 2D-SWE is created by ultrasound-generated pulses from an acoustic radiation force that produce plane shear waves, and the propagation of the resulting shear waves can be captured in real time. 2D-SWE: Two-dimensional shear wave elastography.

2D-SWE | WJG | www.wjgnet.com | Volume 24 | Issue 9 | March 7, 2018 | 960
2D-SWE: Two-dimensional shear wave elastography; 2D-US: Two-dimensional ultrasound; Pen: Penetration; ROI: Region of interest; SWE: Shear wave elastography.

In the future, diagnosis and treatment in such situations will require personalization. The lack of specific criteria may also be due to the paucity of studies, small sample sizes, and diverse research areas; future developments will require more evidence-based medical data from large-scale, multicenter studies. Table 5 includes the cut-off values of LS assessed by 2D-SWE in various studies. Figure 3 shows 2D-SWE of liver fibrosis at METAVIR stages F1 through F4. Note that the LS gradually increases, and the color of the sampling frame gradually changes in the initial stages and incrementally increases in the later stages of fibrosis.

**Diagnosis of NAFLD**

NAFLD is the most prevalent CLD, representing a spectrum ranging from simple fatty liver (SFL) to nonalcoholic steatohepatitis (NASH)\[^{39,40}\]. NAFLD has become a global health problem, with a prevalence comparable to the rates of metabolic syndrome, obesity, type 2 diabetes mellitus and dyslipidemia\[^{41,42}\]. The morbidity and mortality of patients with NAFLD are related to the development of NASH, which may progress to fibrosis and cirrhosis, even resulting in an increased risk of HCC\[^{42}\]. A meta-analysis\[^{44}\] demonstrated that even SFL may result in fibrosis development, and fibrosis development was observed in approximately 30% of patients with SFL, as well as in patients with NASH. Liver fibrosis, but no other histological features, has been demonstrated as the
single most crucial histological feature associated with the risk of liver-related complications and death in patients with NAFLD\(^\text{[45]}\). Therefore, the most important issue for patients with NAFLD is recognizing and assessing the stage of liver fibrosis, which is possible by using US elastography.

Table 4  Summary of the literature for two-dimensional shear wave elastography normal values

| Ref.          | Year | Country | Number | Mean age | Sex, female/male | Mean SWE, standard deviation, range | Remarks |
|---------------|------|---------|--------|----------|------------------|-----------------------------------|---------|
| Muller et al\(^{[19]}\) | 2009 | France  | 15     | NA       | NA               | 2.6-6.2 kPa                       | No data available regarding age or sex of normal subjects |
| Ferraioli et al\(^{[79]}\) | 2012 | Italy   | 42     | 34.8     | 15/29            | 4.92-5.39 kPa                     | Female: 5.7 ± 1.3 kPa |
| Sirli et al\(^{[82]}\) | 2013 | Romania | 82     | 26       | 56/26            | 6.0 ± 1.4 kPa                     | Male: 6.6 ± 1.5 kPa |
|               |      |         |        |          |                  |                                   | BMI ≥ 25 kg/m\(^2\): 6.5 ± 1.5 kPa |
|               |      |         |        |          |                  |                                   | BMI < 25 kg/m\(^2\): 5.8 ± 1.3 kPa |
| Hudson et al\(^{[83]}\) | 2013 | Canada  | 15     | 27       | 5/10             | 5.55 ± 0.74 kPa                   | Female: 5.45 ± 1.02 kPa |
| Wang et al\(^{[84]}\) | 2014 | China   | 30     | 36.1 ± 14.7 | 14/16        | 4.29 kPa                          | Male: 4.89 ± 0.96 kPa |
| Suh et al\(^{[85]}\) | 2014 | South Korea | 196 | 29.2 ± 9.2 | 66/130               | 2.6-6.2 kPa                       | Female: 5.7 ± 0.5 kPa |
| Huang et al\(^{[86]}\) | 2014 | China   | 502    | 37.9     | 310/192          | 5.10 ± 1.02 kPa                   | Male: 5.4 ± 0.7 kPa |
| Yoon et al\(^{[87]}\) | 2014 | South Korea | 122 | NA       | NA               | 5.12 ± 1.46 kPa (session I)       | No data available regarding age or sex of normal subjects |
| Leung et al\(^{[33]}\) | 2013 | China   | 171    | 40.6 ± 10.8 | 103/68        | 5.5 ± 0.7 kPa                     | Male: 5.4 ± 0.7 kPa |
| Franchi-Abella et al\(^{[87]}\) | 2016 | France  | 51     | 0-15     | 26/25            | 6.53 ± 1.38 kPa                   | No significant differences were observed between male and female patients, right and left lobes, or different breathing conditions |

NA: Not available.

Figure 3  Two-dimensional shear wave elastography (Aixplorer US system, SuperSonic Imaging, France) of the liver in chronic hepatitis B patients with liver biopsy-proven fibrosis at METAVIR stages F1 through F4. A: F1 stage, mean Young’s modulus = 5.1 kPa, mean shear wave velocity = 1.3 m/s; B: F2 stage, mean Young’s modulus = 7.4 kPa, mean shear wave velocity = 1.4 m/s; C: F3 stage, mean Young’s modulus = 8.7 kPa, mean shear wave velocity = 1.7 m/s; D: F4 stage, mean Young’s modulus = 11.4 kPa, mean shear wave velocity = 1.9 m/s. Note the liver stiffness gradually increases, and the color of the sampling frame gradually changes in the initial stages and incrementally increases in the later stages of fibrosis. 2D-SWE: Two-dimensional shear wave elastography; US: Ultrasound.
Table 5  Cut-off values of liver stiffness assessed with two-dimensional shear wave elastography in various studies

| Ref.            | Etiologies | Year | Country | Patients, n | F1 (fibrosis) | F2 (significant fibrosis) | F3 (severe fibrosis) | F4 (cirrhosis) |
|-----------------|------------|------|---------|-------------|---------------|---------------------------|----------------------|---------------|
|                 |            |      |         |             | Cut-off, kPa  | AUROC, %       | Cut-off, kPa  | AUROC, %       | Cut-off, kPa  | AUROC, %       | Cut-off, kPa  | AUROC, %       |
| Leung et al[33] | HBV        | 2013 | China   | 454         | 6.5           | 86             | 7.1          | 91             | 7.9          | 93             | 10.1          | 98             |
| Herrmann et al[37] | HBV          | 2017 | Germany | 206         | NA            | NA             | 7.1          | 91             | NA           | NA             | 11.5          | 96             |
| Zeng et al[39]  | HBV        | 2014 | China   | 303         | NA            | NA             | 7.2          | 92             | 9.7          | 95             | 11.7          | 95             |
| Baru et al[40]  | HCV        | 2011 | France  | 113         | NA            | NA             | 9.1          | 95             | 10.1         | 96             | 13.3          | 97             |
| Ferrakos et al[41] | HCV     | 2012 | Italy   | 121         | NA            | NA             | 7.1          | 92             | 8.7          | 98             | 10.4          | 98             |
| Grgurevic et al[46] | CVH     | 2015 | Croatia | 123         | NA            | NA             | 8.1          | 99             | 8.5          | 89             | 10.5          | 88             |
| Cassinotto et al[40] | NAFLD | 2014 | France  | 108         | NA            | NA             | 6.3          | 86             | 8.5          | 89             | 10.5          | 88             |
| Garcovich et al[51] | NAFLD | 2016 | Italy   | 78          | 5.1           | 92             | 6.7          | 96             | NA           | NA             | NA            | NA             |
| Thiele et al[47] | ALD        | 2016 | Denmark | 199         | NA            | NA             | 10.2         | 94             | NA           | NA             | 16.4          | 95             |

2D-SWE: Two-dimensional shear wave elastography; ALD: Alcoholic liver disease; AUROC: Area under the receiver operating characteristic curve; CVH: Chronic viral hepatitis; HBV: Hepatitis B virus; HCV: Hepatitis C virus; LS: Liver stiffness; NA: Not available; NAFLD: Nonalcoholic fatty liver disease.

Cassinotto et al[40] enrolled 291 patients with NAFLD and compared the performance of 2D-SWE, TE and Virtual Touch Quantification using liver biopsy as the reference method. They found that although obesity was related to an increased rate of failed LS measurements, these techniques, especially SWE, were valuable for diagnosing liver fibrosis in patients with NAFLD. The diagnostic performances of 2D-SWE for assessing liver fibrosis are as follows. For a sensitivity of at least 90% for diagnosing significant fibrosis (≥F2), severe fibrosis (≥F3) and cirrhosis (F4), the specificity is approximately 60%-70%; for a specificity of at least 90%, the sensitivity is approximately 50%-70%. 2D-SWE had areas under the receiver operating characteristic curves of 86%, 89% and 88% for the diagnosis of ≥F2, ≥F3 and F4, respectively. Furthermore, LS was mainly related to the fibrosis stage, and steatosis, inflammation and hepatocyte ballooning did not have significant influences on LS. Some NASH patients may have no fibrosis, and SWE may not be useful for the diagnosis of early-stage NASH without fibrosis. Hence, the next question became whether SWE can differentiate NASH from SFL, especially in the early stages of fibrosis. Probably not, and this is an area that relies on biochemical methods. Solutions to these problems will require multifaceted, prospective clinical studies to establish cut-off values for fibrosis staging.

In a study using SWE to identify the diagnostic accuracy of different degrees of fibrosis in 78 pediatric patients with biopsy-proven NASH[47], SWE was shown to be able to accurately evaluate significant liver fibrosis and, less efficiently, mild liver fibrosis in pediatric NAFLD patients. The study suggested that SWE can be used to assess liver fibrosis not only in adults but also in children and adolescents. However, few studies have focused on children; although fibrosis can be detected in children, the stage of fibrosis cannot yet be fully resolved, especially for fibrosis due to fatty liver. Consequently, the technique should be extended to all ages to further demonstrate the stability and reliability of the results.

**Diagnosis of alcoholic liver disease**

Alcoholic liver disease (ALD) is the most common liver disease in the Western world. Chronic and excessive alcohol consumption is responsible for the progression of alcoholic steatosis, hepatitis, fibrosis and cirrhosis. Complete therapy requires abstention from alcohol. Moreover, liver transplantation (LT) remains a life-saving treatment for patients with advanced ALD[48,49]. The EASL published clinical practice guidelines for the management of ALD in 2012[50]. The guidelines noted that elastography is a notable method for the early diagnosis of alcoholic cirrhosis.

A recent prospective study of 199 alcohol-overusing individuals with varying degrees of alcoholic liver fibrosis evaluated two elastography methods for the diagnosis of alcoholic fibrosis and cirrhosis, using liver biopsy as a reference[51]. The study found that 2D-SWE has a high accuracy (area under the curve ≥0.92) for identifying subjects with significant fibrosis and cirrhosis, and the 2D-SWE cut-off values for optimal identification of significant fibrosis and cirrhosis were 10.2 kPa and 16.4 kPa. 2D-SWE was an extremely useful tool for diagnosing alcoholic fibrosis and, furthermore, was more appropriate for diagnosing early cirrhosis than for distinguishing...
between early and advanced cirrhosis. However, the threshold values that will allow the accurate diagnosis of cirrhosis by SWE and obviate the need for liver biopsy in adults with ALD remain to be determined.

Patients with advanced ALD ultimately experience life-threatening complications, such as PH and ascites. These may lead to EGVB, which is among the most important causes of high mortality in patients with cirrhosis\(^{(52)}\). Therefore, assessing the severity of PH during follow-up is essential in patients with cirrhosis. The hepatic venous pressure gradient (HVPG) has been used to assess PH, but it is rarely used in clinical practice because of its invasiveness. A recent study found that LS measured by SWE is an independent predictor of the presence of HCC and esophageal and gastric varices in patients with CLD\(^{(53)}\). Another study demonstrated that SWE, as a promising tool to diagnose PH, has outstanding diagnostic accuracy, with a specificity and sensitivity ranging around 80%, and showed it to be superior to TE\(^{(54)}\); however, more than 30% of the clinically significant PH patients could not be conclusively diagnosed or ruled disease-free because their SWE values were between the cut-offs. Several recent studies have reported that LS measured by SWE in connection with HVPG is important for predicting clinically significant PH in patients with cirrhosis\(^{(55,56)}\). Thus, although 2D-SWE has exceptional clinical value for assessing HCC patients with PH and EGVB, it still cannot replace digestive endoscopy\(^{(52)}\).

**Assessment of end-stage liver disease after LT**

LT is the only therapy for many patients who eventually progress to end-stage liver disease. However, LT is associated with a high rate of complications, which are difficult to identify in the early stages. One study reported a right lobe liver transplant recipient who experienced anastomotic stenosis of the right hepatic vein. SWE was quantitatively used to evaluate stiffness. The results suggested that SWE may be a noninvasive tool for assessing alterations in LS secondary to hepatic venous congestion after LT\(^{(57)}\). Another study showed that SWE may be useful during follow-up after LT. Liver rejection or hepatitis can be predicted at > 4 wk based on liver grafts that are stiffer than normal\(^{(58)}\). In a more recent study, SWE was successfully utilized to monitor the therapeutic effects of direct-acting antivirals in hepatitis C recurrence after LT; the median LS values decreased dramatically after treatment \((P < 0.001)\). The study suggested that SWE is a valid diagnostic tool to follow-up hepatitis C patients undergoing LT\(^{(59)}\).

From this study, we observed that SWE aids in the clinical diagnosis and detection of complications after LT, which represents great progress in SWE technology from diagnosis to monitoring. However, few studies have examined elastography in LT. This study represents the first step, although there is great potential for future research opportunities. Moreover, US elastography should be applied more for monitoring and predicting the complications of LT, particularly for assessing disease progression and prognosis.

**Assessment of focal liver lesions**

Focal liver lesions (FLLs) represent novel lesions for the field of US elastography and include those found in hemangioma, HCC, focal nodular hyperplasia (FNH), metastatic cancer and adenoma. Several studies have reported that 2D-SWE is a useful method for distinguishing FLLs, although it does not completely distinguish benign from malignant lesions\(^{(60-64)}\). The stiffness of lesions in liver malignancies is significantly higher than that of the liver parenchyma and is also higher than that of benign lesions\(^{(60,61)}\) (Figure 4 shows HCC images of 2D-SWE). In malignant tumors, the hardness values of metastases were significantly higher than those found in HCC and cholangiocarcinoma\(^{(62)}\). In benign lesions, 2D-SWE has been regarded as a practical tool for distinguishing FNH from adenoma\(^{(63)}\).

A recent study demonstrated the correct differentiation between benign and malignant FLLs by using real-time 2D-SWE in 96.1% of patients \((area \ under \ the \ curve = 0.98)\)\(^{(64)}\). They used three elastography parameters, the mean stiffness of the FLL, the ratio between the minimal and maximum lesion stiffness, and the ratio between the stiffness of the FLL and the surrounding liver parenchyma to construct a new Liver Elastography Malignancy Prediction score based on a regression analysis. A simpler approach considering only mean lesion stiffness in a dichotomized fashion could be used to diagnose or rule-out malignancy with cut-off values of 14 kPa and 32.5 kPa, respectively.

Nonetheless, conclusions based on the current literature remain unclear. When 2D US and Doppler US suggest that a lesion is a benign tumor but elastography suggests malignancy, the lesion cannot therefore be diagnosed as malignant. Several technical limitations still exist. In situations in which the lesion is smaller than the ROI or located deep or near the heart, the shear wave propagation and imaging stability will be affected. Furthermore, lesion areas with necrotic liquefaction or calcification are not representative of the true lesion stiffness, which often leads to misdiagnosis.

**Assessment of autoimmune liver disease**

Autoimmune liver disease (AILDs) are intricate disorders resulting from the effects of multiple genes in association with environmental factors. The three major AILDs are primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis\(^{(65)}\). As they progress, these diseases may ultimately lead to chronic liver damage, liver fibrosis and cirrhosis. Zeng et al\(^{(66)}\) used liver biopsy as the reference standard for determining the diagnostic accuracy of 2D-SWE for noninvasively assessing liver fibrosis in patients with AILD. Their results indicated that the optimal cut-off values for significant fibrosis \((≥ F2)\), severe fibrosis \((≥ F3)\) and cirrhosis \((F4)\) were 9.7
kPa, 13.2 kPa and 16.3 kPa, respectively. Moreover, the sensitivity and specificity ranged from 75% to 87% for all fibrosis stages. As these data show, SWE has high cut-off values in patients with AILD. The critical cut-off value was obviously higher than that for CHB/CHC. Therefore, different diseases have different thresholds, representing different developmental processes. AILD is relatively rare, and the current study was small; thus, further confirmation is necessary.

These results of LT, FLLs and AILD based on SWE cannot yet be clinically translated, as the research published to date is insufficient to definitively establish diagnostic criteria. However, elastography has shown promise for use in many research and development opportunities and future applications.

**Future perspectives**

Although there is evidence that 2D-SWE could become a crucial tool in end-stage liver disease, additional research and development are necessary. Additional work should focus on the role of SWE not only in cross-sectional diagnosis but also in longitudinal studies considering disease progression, regression and clinical outcomes. Priority should be given to multicenter, large-scale verification research. Indeed, the longitudinal monitoring of fibrosis in patients with CLD may be a highly practical application for SWE. Preliminary research has revealed a remarkable decrease in LS values in patients with chronic viral hepatitis after continued antiviral treatment. Given its high patient acceptance and good accessibility, SWE may also become a convenient tool for identifying patients with liver disease and a promising avenue for future research. However, several issues warrant further consideration.

**The basic problem**

1. Although alternative techniques, such as pSWE/ARFI or 2D-SWE, seem to overcome the limitations of TE, their quality criteria for the staging of liver fibrosis are not yet well defined.

a. It remains unclear whether the shear wave Young’s modulus or shear wave velocity is more representative.
b. It remains unknown whether multiple measurements in one location are necessary when satisfactory measures of stiffness are obtained. Or, whether measurements in more than one location are needed.
c. There is currently no agreement on objective quality criteria regarding what constitutes a valid measurement and what is an invalid measurement.

2. It remains unknown whether a simple semi-quantitative fibrosis score can adequately reflect the complexity of the pathophysiological process.

**The clinical questions**

1. In the era of promotion of precision medicine, can 2D-SWE accurately guide clinical work to aid in the design of an antiviral therapy for hepatitis B patients?
2. Can 2D-SWE be a reliable measurement of the prognosis of liver fibrosis?
3. Does a greater Young’s modulus indicate more serious disease progression? Does a reduced Young’s modulus indicate disease remission or effective treatment?
4. How do we diagnose the mixed types of liver disease?
5. In adult patients with NAFLD, what SWE LS cut-off value allows us to accurately diagnose the presence of cirrhosis and eliminate the need for liver biopsy?
6. In compensated cirrhosis of adult CLD, what 2D-SWE liver stiffness cut-off value allows us to avoid the need for gastroscopy?
7. Focal lesions can lead to erroneous results. How should these be resolved?

**Patient follow-up questions**

1. During follow-up monitoring, are there any definite cut-off values to weigh the progression, regression and outcome of liver disease?
2. What is a minimal time span for measuring LS over time? How often should measurements be performed?
3. How should elastography be used to predict the risk for HCC in patients with cirrhosis, regardless of etiology?
Here, we will address the first clinical issue. On the basis of the current study, we believe that SWE can guide clinical work to help develop a reasonable treatment strategy for patients with CLDs by measuring the degree of LS, which reflects the degree of liver fibrosis, and by monitoring the progress of the disease in real time. According to the EASL guidelines, it is of particular significance to identify patients with cirrhosis, as their treatment regimen and posttreatment surveillance must be adapted. The latest report from a European, 10-center, cohort study of 1951 adult Caucasian CHB patients found that HCC incidence distinctly dropped after the first 5 years of therapy, particularly in those with compensated cirrhosis. Furthermore, multivariable analysis showed that a LS ≥ 12 kPa at year 5 was related to greater HCC development after year 5, which likely represents valuable indirect markers of the severity of liver disease. Consequently, we believe that SWE can reflect liver fibrosis and guide therapy, thus decreasing the risk of HCC and remarkably improving the prognosis. This represents a major advancement in the treatment of CLD.

2D-SWE is known to be a multifactorial technique that factors in the anatomy of the liver, the physical characteristics and the underlying illness of the patient, the experience of the examiner, and differences in equipment. The following details include the factors associated with SWE reliability and ways to improve its performance in liver applications.

**Anatomy of the liver**
The liver is located in the upper abdomen, near the heart, lungs and gastrointestinal tract, and is particularly affected by respiratory movements as well as the heartbeat and gas in the gastrointestinal tract. Measurements of the left liver lobe yield markedly higher values and are more variable than the right lobe; thus, LSM in the left liver lobe should be avoided whenever possible. During the examination, the patient needs to cooperate by holding their breath (neither in the expiratory phase nor in the aspirated phase) to stabilize the 2D image measurement because stable 2D imaging is the basis of successful results.

**Physical characteristics and underlying illness of the patient**
Previous studies have reported that SWE measurements are not affected by a high body mass index, ascites or fatty liver, while in clinical practice, high measurement failure rates are due to obesity or ascites causing poor penetration. Obese patients often have a fatty liver with a thick layer of subcutaneous fat and echo attenuation throughout the liver, which is not conducive to clear 2D imaging. In some very thin patients with a narrow intercostal space, especially patients who have entered the end-stage of liver cirrhosis, the right liver has been severely reduced to the extent that it affects elasticity measurements.

Using current methods, according to the patient’s liver, the depth should be dropped, and the image should be appropriately enlarged while the areas of the sampling frame and ROI are adjusted to the shrinking liver. In addition, some factors influence the LS measured by elastography, leading to an overestimation of liver fibrosis. Such factors include excessive alcohol intake, elevated central venous pressure, cardiac failure, intra- or extrahepatic cholestasis, alanine aminotransferase flare in acute or chronic hepatitis, and histological necroinflammation activity.

**Operator experience**
LS measurements by 2D-SWE should be made by an expert operator. It has been reported that experienced examiners have higher reproducibility of measurements than novice examiners. It is advised that at least 50 supervised 2D-SWE measurements should be performed by beginners in order to acquire reliable results. This issue therefore necessitates strict prejob training for operators to reduce the error caused by lack of experience and to improve the stability of clinical implementations (Figure 5 shows an analysis of failed measurements).

**Differences in manufacturer equipment**
There may be significant variation in the frequency of acoustic radiation forces used across manufacturers, although variations can even be observed across different equipment from the same manufacturer or due to different settings applied using the same equipment. Large differences among the measurements provided by different settings create obstacles to the clinical application of SWE that need to be addressed in the future. In summary, these techniques need to be performed using a standardized protocol with critically interpreted results, taking confounding factors into account.

**CONCLUSION**
In conclusion, 2D-SWE appears to be a valid, simple, rapid and reproducible method for the noninvasive assessment of liver fibrosis, with advantages including its low cost and widespread availability. As liver biopsies cannot be performed frequently, SWE can be used to regularly monitor liver fibrosis over the long term. SWE is a promising technology with potential clinical applications, including accurate quantification and therapeutic monitoring. We believe that with the popularity of US elastography, the noninvasive assessment of liver fibrosis will be further promoted. Most importantly, in the future, SWE may become a routine method of screening for patients with CLDs. Finally, large-scale, multicenter, multifield clinical studies are needed to explore the applications of SWE, as there may be variability in terms of demographics, disease and liver cancer incidence predictions. We are
Figure 5  Analysis of failed measurements. A: A 68-year-old female who had right heart failure and could not hold her breath, causing the failed liver stiffness measurement; B: An image acquired by an inexperienced operator who did not set the standard parameters.

hopeful that SWE will continue to evolve and attain a utility equal to that of Doppler as a new mode of US imaging.

REFERENCES

1. Singh S, Muir AJ, Dieterich DT, Falck-Ytter YT. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. Gastroenterology 2017; 152: 1544-1577 [PMID: 28442120 DOI: 10.1016/j.gastro.2017.03.016]

2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-171 [PMID: 25350442 DOI: 10.1016/s0140-6736(14)61682-2]

3. Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut 2015; 64: 830-841 [PMID: 25681399 DOI: 10.1136/gutjnl-2014-306842]

4. Friedrich-Rust M, Poynard T, Castéra L. Critical comparison of elastography methods to assess chronic liver disease. Rev Gastroenterol Hepatol 2016; 13: 402-411 [PMID: 27273167 DOI: 10.1038/rgastro.2016.86]

5. Stasi C, Milani S. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. World J Gastroenterol 2016; 22: 1711-1720 [PMID: 26819535 DOI: 10.3748/wjg.v22.i4.1711]

6. Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 2014; 20: 16820-16830 [PMID: 25492996 DOI: 10.3748/wjg.v20.i45.16820]

7. Seeff LB, Eversen GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana D, Bator RF, Romm HL, Dienstag JL; HALT-C Trial Group. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8: 877-883 [PMID: 20362695 DOI: 10.1016/j.cgh.2010.03.025]

8. Sichion Lde L, Narciso-Schiavon JL, de Carvalho-Filho RJ. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol 2014; 20: 2854-2866 [PMID: 24659877 DOI: 10.3748/wjg.v20.i13.2854]

9. Cassinotto C, Lapuyade B, Moursies A, Hiriart JB, Vergnol J, Gaye D, Castain C, Le Bail B, Chermak F, Foucher J, Laurent F, Montaudon M, De Ledinghen V. Non-invasive assessment of liver fibrosis with impulse elastography: comparison of Supersonic Shear Imaging with ARFI and FibroScan®. J Hepatol 2014; 61: 550-557 [PMID: 24815876 DOI: 10.1016/j.jhep.2014.04.044]

10. Dietrich CF, Bamber J, Bezziottti A, Bota S, Cantisani V, Castera L, Cosgrove D, Ferraioli G, Friedrich-Rust M, Gilja OH, Goertz RS, Karlas T, de Knecht R, de Ledinghen V, Piscaglia F, Procopet B, Saftoiu A, Sidhu PS, Sporea I, Thiele M. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). Ultraschall Med 2017; 38: e16-e47 [PMID: 28407655 DOI: 10.1055/s-0043-1335205]

11. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALERT Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-264 [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006]

12. Bamber J, Cosgrove D, Dietrich CF, Frommageau G, Bojunga J, Calliada F, Cantisani V, Correas JM, D’Onofrio M, Drakonaki EE, Fink M, Friedrich-Rust M, Gilja OH, Havre RF, Jensen C, Krauser AS, Ohlinger R, Saftoiu A, Schaefer F, Sporea I, Piscaglia F. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: Basic principles and technology. Ultraschall Med 2013; 34: 169-184 [PMID: 23558397 DOI: 10.1055/s-0033-1335205]

13. Castéra L, Foucher J, Bernard PH, Carvalho F, Allaux D, Merrouche W, Couzigou P, de Ledinghen V. Pitfalls of liver fibrosis measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51: 828-835 [PMID: 20063276 DOI: 10.1002/hep.23425]

14. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-974 [PMID: 18395077 DOI: 10.1053/j.gastro.2008.01.034]

15. Haque M, Robinson C, Owen D, Yoshida EM, Harris A. Comparison of acoustic radiation force impulse imaging (ARFI) to liver biopsy histologic scores in the evaluation of chronic liver disease: A pilot study. Ann Hepatol 2010; 9: 289-293 [PMID: 20720270]

16. Singh S, Venkatesh SK, Wang Z, Miller FH, Motosiugi U, Low RN, Hassanein T, Asbach P, Godfrey EM, Yin M, Chen J, Keaveny AP, Bridges M, Bohte A, Murad MH, Lomas DJ, Talwalkar JA, Ethman RL. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 2015; 13: 440-451.e6 [PMID: 25305449 DOI: 10.1016/j.cgh.2014.09.046]

17. Huwart L, Sempoux C, Vicaut E, Salameh N, Amet L, Danse E, Peeters F, ter Beek LC, Rahier J, Sinkus R, Horsmans Y, Van Beers BE. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008; 135: 32-40 [PMID: 18471441 DOI: 10.1016/j.gastro.2008.03.076]

18. Bavi E, Gennisson JL, Couarde M, Bercov J, Mallet V, Fink M, Baelde A, Vallet-Pichard A, Alpaks B, Tanter M, Psol S. Noninvasive in vivo liver fibrosis evaluation using supersonic shear imaging: a clinical study on 113 hepatitis C virus patients. Ultrasound Med
Stahler A, Hafidaddottir S, Bendtsen F. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2015; 149: 169-176 e1 [PMID: 25935633 DOI: 10.1053/j.gastro.2015.04.043].

Cassino C, Boursier J, de Lédinghen V, Libeigt J, Lapuyade B, Calès P, Hirtzb J, Michalak S, Bail BL, Carter V, Moursies A, Oberti F, Fouchard-Hubert I, Vergniol J, Aubé C. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. *Hepatology* 2016; 63: 1817-1827 [PMID: 26569452 DOI: 10.1001/hep.28394].

Garcovich M, Veraldi S, Di Stasio E, Zocco MA, Monti L, Tomà P, Pompi M, Gasharrini A, Nobi A, Visoni L. Liver Stiffness in Pediatric Patients with Fatty Liver Disease: Diagnostic Accuracy and Reproducibility of Shear-Wave Elastography. *Radiology* 2017; 283: 820-827 [PMID: 27982761 DOI: 10.1148/radiol.2016161002].

Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver disease. *J Hepatol* 2013; 59: 160-168 [PMID: 23511777 DOI: 10.1016/j.jhep.2013.03.007].

Mueller S, Seitz HK, Rauch V. Non-invasive diagnosis of alcoholic liver disease. *World J Gastroenterol* 2014; 20: 14626-14641 [PMID: 25535602 DOI: 10.3748/wjg.v20.i40.14626].

European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. *J Hepatol* 2012; 57: 399-420 [PMID: 22633836 DOI: 10.1016/j.jhep.2012.04.004].

Thiele M, Dietlese S, Sevelsted Møller L, Madsen BS, Fuglsang Hansen J, Fialla AD, Trebicka J, Krag A. Transient and 2-Dimensional Shear-Wave Elastography Provide Comparable Assessment of Alcoholic Liver Fibrosis and Cirrhosis. *Gastroenterology* 2016; 150: 123-133 [PMID: 26435270 DOI: 10.1053/j.gastro.2015.09.040].

Tripathi D, Stanley AJ, Hayes PC, Patch D, Milson C, Mehrzad H, Austin A, Ferguson JW, Oliff SP, Hudson M, Christie JM. Clinical Services and Standards Committee of the British Society of Gastroenterology. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. *Gut* 2015; 64: 1680-1704 [PMID: 25887380 DOI: 10.1136/gutjnl-2015-309262].

Kasai Y, Moriyasu F, Saito K, Hara T, Kobayashi Y, Nakanura I, Sugimoto K. Value of shear wave elastography for predicting hepatic fibrosis carcinoma and esophageal varices in patients with chronic liver disease. *J Med Ultrasound (2001)* 2015; 42: 349-355 [PMID: 26576786 DOI: 10.1093/jmuls/2001.4.0063-03].

Jansen C, Bogs C, Verlinden W, Thiele M, Möller P, Görtzen Y. The risk of hepatocellular carcinoma decreases with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet* 2013; 381: 468-475 [PMID: 23234725 DOI: 10.1016/S0140-6736(12)64251-5].

Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. *J Hepatol* 2014; 60: 210-223 [PMID: 24084655 DOI: 10.1016/j.jhep.2013.09.020].

Zeng J, Huang ZP, Zheng J, Wu T, Zheng RQ. Non-invasive assessment of liver fibrosis using two-dimensional shear wave elastography in patients with autoimmune liver diseases. *World J Gastroenterol* 2017; 23: 4839-4846 [PMID: 28765706 DOI: 10.3748/wjg.v23.i26.4839].

Grgurević I, Bokun T, Salkic NN, Brkljacic B, Vukeljić-Markovic M, Stoos-veic T, Aralica G, Rakic M, Filipicc-kanižaj T, Berzigotti A. Liver elastography malignancy prediction score for noninvasive characterization of focal liver lesions. *Liver Int* 2017; Epub ahead of print [PMID: 29028279 DOI: 10.1111/hij.13611].

Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. *J Hepatol* 2014; 60: 210-223 [PMID: 24084655 DOI: 10.1016/j.jhep.2013.09.020].

Brunel T, Guibal A, Boularan C, Ducerf C, Mabrut JY, Bancel B, Bouselle R, Rode A. Focal nodular hyperplasia and hepatocellular adenoma: The value of shear wave elastography for differential diagnosis. *Eur J Radiol* 2015; 84: 2059-2064 [PMID: 26299323 DOI: 10.1016/j.ejrad.2015.07.029].

Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson CB, Cavalcoli F, Frasseli M, Conte D, Massironi S. Two-dimensional shear-wave elastography of the liver and spleen: a prospective multicentre study. *Eur J Radiol* 2013; 84: 529-536 [PMID: 23300037 DOI: 10.1016/j.ejrad.2013.03.010].

Oberti F, Fouchard-Hubert I, Vergniol J, Aubé C. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. *Hepatology* 2013; 57: 769-775 [PMID: 23278357 DOI: 10.1002/hep.26290].

Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. *J Hepatol* 2014; 60: 210-223 [PMID: 24084655 DOI: 10.1016/j.jhep.2013.09.020].

Hartl J, Denzer U, Ehlken H, Zenouzi R, Peiseler M, Sebode M, Hubener S, Pannicke N, Weiler-Normann C, Quaas A, Lohse AW, Schramm C. Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. *J Hepatol* 2016; 65: 769-775 [PMID: 27238753 DOI: 10.1016/j.jhep.2015.05.023].

Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Keskin O, Gatselis N, Hansen BE, Lehretz M, de la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yardydlin C, Berg T, Colombo M, Esteban R, Janssen HLA, Lampertico P. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. *Hepatology* 2016; 64: 1444-1453 [PMID: 28622419 DOI: 10.1002/hep.29320].

Cosgrove D, Piscaglia F, Bamber J, Bojunga J, Correas JM, Gilja OH, Kaufer AS, Sporea I, Callida F, Cantisani D, Onofrio M, Drakonaki EE, Fink M, Friedrich-Rust M, Fromageau J, Havre RF, Jensen C, Ohlinger R, Sáfolia A, Schaefer F, Dietrich CF; EFUMB. EFUMB guidelines and recommendations for the diagnosis of focal liver lesions by shear wave elastography.
on the clinical use of ultrasound elastography. Part 2: Clinical applications. *Ultrasonic Med 2013; 34: 238-253* [PMID: 23605169 DOI: 10.1055/s-0033-1355375]

72. Karlas T, Pfrepper C, Wiegand J, Wittekind C, Neuschulz M, Mössner J, Berg T, Tröltzsch M, Keim V. Acoustic radiation force impulse imaging (ARFI) for non-invasive detection of liver stiffness: examination standards and evaluation of interlobe differences in healthy subjects and chronic liver disease. *Scand J Gastroenterol* 2011; 46: 1458-1467 [PMID: 21916815 DOI: 10.3109/00365521.2011.610004]

73. Suh CH, Kim SY, Kim KW, Lim YS, Lee SJ, Lee MG, Lee J, Lee SG, Yu E. Determination of normal hepatic elasticity by using real-time shear-wave elastography. *Radiology* 2014; 271: 895-900 [PMID: 24555633 DOI: 10.1148/radiol.14131251]

74. Mueller S, Millonig G, Sarovska L, Friedrich S, Reimann FM, Pritsch M, Eisele S, Stickel F, Longerich T, Schirmacher P, Seitz HK. Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. *World J Gastroenterol* 2010; 16: 966-972 [PMID: 20180235 DOI: 10.3748/wjg.v16.i8.966]

75. Millonig G, Friedrich S, Adolf S, Fonouni H, Golriz M, Mehrabi A, Stiefel P, Pöschl G, Büchler MW, Seitz HK, Mueller S. Liver stiffness is directly influenced by central venous pressure. *J Hepatol* 2010; 52: 206-210 [PMID: 20022130 DOI: 10.1016/j.jhep.2009.11.018]

76. Millonig G, Reimann FM, Friedrich S, Fonouni H, Mehrabi A, Büchler MW, Seitz HK, Mueller S. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. *Hepatology* 2008; 48: 1718-1723 [PMID: 18836992 DOI: 10.1002/hep.22577]

77. Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, Moscarella S, Boddi V, Petrarca A, Laffi G, Marra F, Pinzani M. Acute viral hepatitis increases liver stiffness values measured by transient elastography. *Hepatology* 2008; 47: 380-384 [PMID: 18095306 DOI: 10.1002/hep.22207]

78. Fraquelli M, Rigamonti C, Casazza G, Donato MF, Ronchi G, Conte D, Rumi M, Lampertico P, Colombo M. Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. *J Hepatol* 2011; 54: 621-628 [PMID: 21146243 DOI: 10.1016/j.jhepat.2011.07.017]

79. Ferraioli G, Tinelli C, Zicchetti M, Above E, Poma G, Di Gregorio M, Filice C. Reproducibility of real-time shear wave elastography in the evaluation of liver elasticity. *Eur J Radiol* 2012; 81: 3102-3106 [PMID: 22749107 DOI: 10.1016/j.ejrad.2012.05.030]

80. Zhuang Y, Ding H, Zhang Y, Sun H, Xu C, Wang W. Two-dimensional Shear-Wave Elastography Performance in the Noninvasive Evaluation of Liver Fibrosis in Patients with Chronic Hepatitis B: Comparison with Serum Fibrosis Indexes. *Radiology* 2017; 283: 873-882 [PMID: 27982760 DOI: 10.1148/radiol.2016160131]

81. Piscaglia F, Salvatore V, Mulazzani L, Cantisani V, Colecchia A, Di Donato R, Feliciani C, Ferrarini A, Gamal N, Grasso V, Marasco G, Mazzotta E, Ravaiol F, Ruggieri G, Serio I, Sitoouk Nkamgho JF, Serra C, Festi D, Schiavone C, Bolondi L. Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study. *Dig Liver Dis* 2017; 49: 802-808 [PMID: 28365330 DOI: 10.1016/j.dld.2017.03.001]

82. Sirili R, Bota S, Sporea I, Jurchis A, Popescu A, Gradinaru-Tascău O, Szilaski M. Liver stiffness measurements by means of supersonic shear imaging in patients without known liver pathology. *Ultrasound Med Biol* 2013; 39: 1362-1367 [PMID: 23743106 DOI: 10.1016/j.ultrasmedbio.2013.03.021]

83. Hudson JM, Milor L, Parry C, Williams R, Burns PN. Inter- and intra-operator reliability and repeatability of shear wave elastography in the liver: a study in healthy volunteers. *Ultrasound Med Biol* 2013; 39: 950-955 [PMID: 23453379 DOI: 10.1016/j.ultrasmedbio.2012.12.011]

84. Wang CZ, Zhang J, Huang ZP, Xiao Y, Song D, Zeng J, Zheng HR, Zheng RQ. Influence of measurement depth on the stiffness assessment of healthy liver with real-time shear wave elastography. *Ultrasound Med Biol* 2014; 40: 461-469 [PMID: 24361224 DOI: 10.1016/j.ultrasmedbio.2013.10.021]

85. Huang Z, Zheng J, Zeng J, Wang X, Wu T, Zheng R. Normal liver stiffness in healthy adults assessed by real-time shear wave elastography and factors that influence this method. *Ultrasound Med Biol* 2014; 40: 2549-2555 [PMID: 25282481 DOI: 10.1016/j.ultrasmedbio.2014.05.008]

86. Yoon JH, Lee JM, Han JK, Choi BI. Shear wave elastography for liver stiffness measurement in clinical sonographic examinations: evaluation of intraobserver reproducibility, technical failure, and unreliable stiffness measurements. *J Ultrasound Med* 2014; 33: 437-447 [PMID: 24567455 DOI: 10.7863/ultra.33.3.437]

87. Franchi-Abella S, Corno L, Gonzales E, Antoni G, Fabre M, Ducot B, Pariente D, Gennisson JL, Tanter M, Corrães J. Feasibility and Diagnostic Accuracy of Supersonic Shear-Wave Elastography for the Assessment of Liver Stiffness and Liver Fibrosis in Children: A Pilot Study of 96 Patients. *Radiology* 2016; 278: 554-562 [PMID: 26305193 DOI: 10.1148/radiol.2015142815]
